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Alzheimer’s disease - a neurospirochetosis.
Analysis of the evidence following Koch’s and
Hill’s criteria
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Abstract
It is established that chronic spirochetal infection can cause slowly progressive dementia, brain atrophy and
amyloid deposition in late neurosyphilis. Recently it has been suggested that various types of spirochetes, in an
analogous way to Treponema pallidum, could cause dementia and may be involved in the pathogenesis of
Alzheimer’s disease (AD). Here, we review all data available in the literature on the detection of spirochetes in AD
and critically analyze the association and causal relationship between spirochetes and AD following established
criteria of Koch and Hill. The results show a statistically significant association between spirochetes and AD (P = 1.5
×1 0
-17, OR = 20, 95% CI = 8-60, N = 247). When neutral techniques recognizing all types of spirochetes were used,
or the highly prevalent periodontal pathogen Treponemas were analyzed, spirochetes were observed in the brain
in more than 90% of AD cases. Borrelia burgdorferi was detected in the brain in 25.3% of AD cases analyzed and
was 13 times more frequent in AD compared to controls. Periodontal pathogen Treponemas (T. pectinovorum,
T. amylovorum, T. lecithinolyticum, T. maltophilum, T. medium, T. socranskii) and Borrelia burgdorferi were detected
using species specific PCR and antibodies. Importantly, co-infection with several spirochetes occurs in AD. The
pathological and biological hallmarks of AD were reproduced in vitro by exposure of mammalian cells to
spirochetes. The analysis of reviewed data following Koch’s and Hill’s postulates shows a probable causal
relationship between neurospirochetosis and AD. Persisting inflammation and amyloid deposition initiated and
sustained by chronic spirochetal infection form together with the various hypotheses suggested to play a role in
the pathogenesis of AD a comprehensive entity. As suggested by Hill, once the probability of a causal relationship
is established prompt action is needed. Support and attention should be given to this field of AD research.
Spirochetal infection occurs years or decades before the manifestation of dementia. As adequate antibiotic and
anti-inflammatory therapies are available, as in syphilis, one might prevent and eradicate dementia.
Keywords: Alzheimer’s disease, bacteria, Borrelia burgdorferi, dementia, infection, Lyme disease, periodontal
pathogen, spirochetes, Treponema, syphilis
Introduction
The recognition that pathogens can produce slowly pro-
gressive chronic diseases has resulted in a new concept of
infectious diseases. The pioneering work of Marshall and
Warren has established that Helicobacter pylori (H. pylori)
causes stomach ulcer [1]. Also the etiologic agent of
Whipple’s disease was revealed to be another bacterium,
Tropheryma whippeli. Recent reports have documented
that infectious agents also occur in atherosclerosis, cardio-
and cerebrovascular disorders [2-10], diabetes mellitus
[11-16], chronic lung [17-20] and inflammatory bowel
diseases [1,21-25], and various neurological and neuropsy-
chiatric disorders [26-31].
Nearly a century ago, Fischer, Alzheimer and their col-
leagues [32,33] discussed the possibility that microorgan-
i s m sm a yp l a yar o l ei nt h ef o rmation of senile plaques.
Historic data indicate that the clinical and pathological
hallmarks of syphilitic dementia in the atrophic form of
general paresis, caused by chronic spirochetal infection,
are similar to those of AD. There is an increasing amount
of data that indicates that spirochetes are involved in the
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new data related to the involvement of spirochetes in
AD. The goal was to critically analyze the association and
causality between spirochetes and AD, based on the sub-
stantial amount of data available and on established cri-
teria of Koch [34,35] and Hill [36]
Pathological hallmarks and pathogenesis of
Alzheimer disease
AD is the most frequent cause of dementia and is charac-
t e r i z e db yas l o w l yp r o g r e s s i v ed e c l i n eo fc o g n i t i o na n d
memory. Alzheimer described the characteristic cortical
senile plaques and neurofibrillary tangles in the brain of a
51-year-old woman who suffered from presenile demen-
tia [37]. Recently, it was pointed out that the presenile
form, with onset before age 65, is identical to the most
common form of senile dementia [38,39]. Therefore
today the term AD is used for the designation of both
presenile and senile cases.
The pathological hallmarks of AD are progressive brain
atrophy and the accumulation of cortical senile plaques
and neurofibrillary tangles. A fibrillary amyloid substance
is deposited in senile plaques, formed by the aggregation
of the 4.2-kD amyloid beta peptide (Ab). Ab is derived by
proteolytic cleavage from a transmembrane amyloid beta
precursor protein (AbPP). Neurofibrillary tangles contain
paired helical filaments (PHFs), and the major compo-
nent of PHFs is the microtubule associated protein tau.
Granulovacular degeneration is another characteristic
alteration of neurons in AD.
The origins of Ab deposition, neuronal tangle formation
and granulovacuolar degeneration still remain unclear. Var-
ious hypotheses were proposed to explain the pathogenesis
of AD [40,41]. Mutations in AbPP, presenilin 1 and prese-
nilin 2 genes are implicated in inherited, early onset AD,
but the frequency of familial cases is very low [42]. The
epsilon 4 allele of apolipoprotein E (ApoE4) was revealed to
be a risk factor for AD [43]. Polymorphisms of various
genes, including numerous inflammatory genes [44] are
associated with AD. The AlzGene database (http://www.
alzgene.org) assembles and organizes the increasing num-
ber of AD related susceptibility genes [45]. It provides a
comprehensive, unbiased and regularly updated data on
genetic studies performed in AD, including meta-analyses
for various polymorphisms related to AD.
The relationship between the two major biological
markers of AD Ab and hyperphosphorylated tau is not
clear. That the soluble form of Ab and tau strongly
interact [46] and that AbPP is also expressed in neurofi-
brillary tangles [47] suggest that these apparently differ-
ent pathologies are linked in AD.
The critical role of chronic inflammation in AD is
now widely recognized. The important role of neuroin-
flammation and the importance of IL-1 signaling were
first documented by McGeer, Rogers and Griffin
[48-50]. Cellular and molecular components of the
immune system reactions including the membrane
attack complex (MAC, C5b-9) are associated with AD
cortical lesions [51-54] and non-steroidal anti-inflamma-
tory drugs (NSAIDs) reduce the risk of 55-80% for AD
[55-57].
The clinical and pathological hallmarks of AD are
similar to those of the atrophic form of general
paresis
Historic observations show that the clinical and patholo-
gical hallmarks of AD are similar to those occurring in
the atrophic form of general paresis [58,59]. Noguchi
and Moore [60] by showing the presence of T. pallidum
in the cerebral cortex of patients with general paresis
provided the conclusive evidence that T. pallidum is
responsible for slowly progressive dementia, cortical
atrophy and local amyloidosis in the atrophic form of
this chronic bacterial infection.
This form of general paresis is characterized by a dif-
fuse, predominantly frontotemporal cortical atrophy. The
characteristic pathological features comprise severe neu-
ronal loss, reactive microgliosis and astrocytosis. Spiro-
chetes form plaque-like cortical masses or colonies
[61,62]. Pacheco e Silva [61,62] by analyzing the brains of
more than 60 patients with atrophic general paresis
reported that the number of spirochetes and spirochetal
plaques increased with the severity of cortical atrophy.
The morphology and distribution of T. pallidum colonies
are identical to those of senile plaques. Spirochetes are
more numerous in the hippocampus and frontal cortex
[61,62] and accumulate without accompanying lympho-
plasmocytic infiltrates. Another characteristic feature of
the atrophic form of general paresis is the accumulation
in the brain of “paralytic iron” [63]. Neurofibrillary tan-
gles and amyloid deposition both occur in dementia
paralytica [59,64-66]. Recent analysis of archival brain
material of clinically and pathologically confirmed gen-
eral paretic cases revealed that the local amyloid deposit
in general paresis, as in AD, consists of Ab [67].
Association of spirochetes and Alzheimer’s
disease
That dementia associated with cortical atrophy and
microgliosis also occurs in late stages of Lyme disease
[68-73] caused by Borrelia burgdorferi (B. burgdorferi),
suggested that various types of spirochetes in an analo-
gous way to T. pallidum might cause dementia and
brain pathology similar to AD.
Various Borrelia and Treponema species from the
family Spirochaetaceae are responsible for diverse human
diseases. From 36 known Borrelia species 12 cause Lyme
disease or other borreliosis, which is transmitted by the
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20 species of Borrelia recurrentis and is transmitted by
ticks and lice [74,75]. Near 60 diverse Treponema species
were identified in subgingival pockets in human period-
ontal diseases [76,77]. These periodontal pathogen spiro-
chetes comprise Treponema denticola, Treponema
socranskii, Treponema pectinovorum, Treponema amylo-
vorum, Treponema lecithinolyticum, Treponema malto-
philum and Treponema medium. Treponema vincentii
causes necrotizing fusospirochetal disease called Vincent
angina. Many other Treponema species are present in
the human genital mucosa. From the family Brachyspira-
ceae, two species of the genus Brachyspira (B.), i.e. B. aal-
borgi and B. (Serpulina) pilosicoli are responsible for
human intestinal spirochetosis [78,79]. Spirochetes of the
genus Leptospira, family Leptospiraceae, cause human
leptospirosis.
Detection of all types of spirochetes
To verify the hypothesis that several types of spirochetes
may be involved in AD, 147 AD cases and 37 controls
were analyzed using neutral techniques, which recognize
all types of spirochetes.
In an initial study, helically shaped microorganisms
were observed in 14 AD cases in the cerebrospinal fluid
(CSF), blood and cerebral cortex [70]. They were isolated
from the cerebral cortex, and cultivated from the blood
in a modified Noguchi medium, which enables the culti-
vation of anaerobic spirochetes. They were absent in age-
matched controls, which were without any AD-type cor-
tical changes [70]. In three AD cases, spirochetes were
also cultivated from the cerebral cortex in a synthetic
Barbour-Stoenner-Kelly II (BSK II) medium [70]. Further
scanning electron microscopy and atomic force micro-
scopy analyses defined that these helically shaped micro-
organisms possess endoflagella and taxonomically belong
to the order Spirochaetales [80]. Spirochetes were
detected in the brains of 8 AD patients derived from
another laboratory and in the blood of 5 living patients
with AD-type dementia [81]. In addition to dark field,
atomic force, electron and immune-electron microscopy
analyses, immunohistochemical detection of spirochetes
was also performed using spirochete and bacterial pepti-
doglycan (PGN) specific antibodies, and by using the
nonspecific DNA marker 4’,6-Diamidine-2’-phenylindole
dihydrochloride (DAPI) and species-specific DNA as
revealed by in situ hybridization (ISH) [70,80-86]. PGN is
the building block of the cell wall of virtually all Eubac-
teria, including spirochetes, however, Mycoplasma and
Chlamydia, which lack bacterial cell wall, do not show
detectable PGN [87,88]. The morphology of helically
shaped microorganism detected by spirochete or PGN
specific antibodies is identical [compare Fig. seven G and
H of reference 89]. PGN-immunoreactive helically
shaped spirochetes were detected in the brains in 32 defi-
nite AD cases and in 12 cases with mild or moderate
AD-type cortical changes [87,88]. Spirochetes were
observed in senile plaques, neurofibrillary tangles, curly
fibers and in the wall of cortical or leptomeningeal
arteries exhibiting amyloid deposits [70,80-82]. Spiro-
chete and PGN specific antigens were co-localized with
Ab [83,85]. Control brains without AD-type cortical
changes were negative [70,83-85]. These observations
have suggested that various types of spirochetes of the
order Spirochaetales, might cause dementia and contri-
bute to the pathogenesis of AD.
McLaughlin et al., [90] did not find spirochetes by
dark field and electron microscopy in the brains of 7
AD cases tested. They observed spirochetes in the blood
in one of 22 clinically diagnosed AD patients (Table 1).
The spirochete illustrated by the authors corresponds to
a regularly spiral vegetative form. It is not clear, whether
the atypical, pleomorphic spirochete forms, which are
c o m m o ni nb l o o da n di ni n f e c t e dt i s s u e s[ 8 9 , 9 1 - 9 3 ]
were considered or not in this study. The authors have
suggested that the spirochete observed could correspond
to oral Treponema.
In all these studies, which detected spirochetes using
neutral techniques, 680 brain and blood samples were ana-
lyzed. In AD, more than 91.1% (451/495) of the samples
were positive, while the 185 control samples were all
negative.
Periodontal pathogen spirochetes
Oral anaerobic Treponema (T) spirochetes are predomi-
nant periodontal pathogens, which are highly prevalent in
the population. Several of them revealed to be invasive in
vivo and in vitro [94,95]. Six different periodontal patho-
gen spirochetes, specifically, T. denticola, T. pectinovorum,
T. vincenti, T. amylovorum, T. maltophilum, T. medium
and T. socranskii were detected in the brains of AD
patients using species specific PCR. At least one oral Tre-
ponema species was detected in 14 of 16 AD cases, and in
4 of 18 controls [96]. Species-specific antigens of T. pecti-
novorum and T. socranskii were observed in 15 AD and in
7 controls (P < 0.001). Six different Treponema species
were detected in the brain in one AD patient, five species
in four, four or three species each in one, and one species
in seven AD cases. Of the four controls with Treponema
spirochetes, one had two Treponema species and three
one species each. The number of diverse Treponema spe-
cies was significantly higher in the brains of AD patients
compared to controls [96]. Treponema antigens were
detected both in the hippocampus and frontal cortex.
These important results, as proposed earlier [70,80-82],
indicate that periodontal pathogen spirochetes in an
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brain, persist in the brain and cause dementia. They also
indicate that co-infection by several spirochetes occurs in
AD. These findings are in agreement with recent observa-
tions showing an association between periodontal diseases
and AD [97].
Borrelia burgdorferi
B. burgdorferi was first cultivated from the brain in two
AD patients by MacDoald and Miranda [98] and MacDo-
nald [99] and in 3 definite AD cases by Miklossy [85]
(Table 1). Extensive characterization of the cultivated spir-
ochetes confirmed, that the morphological, histochemical
Table 1 Detection of spirochetes in Alzheimer disease
Authors N Mat Meth AD CTRL Cult Serol
Detection of all types of spirochetes
Miklossy, 1993 & Miklossy et al., 1994 [70,80] 27 Brain, Bl, CSF DF, HC, IHC, EM, AFM 14/14 0/13** 14/14 (Bl 4/5) Nd
Miklossy, 1994 [81] 12
5
Brain
Bl
DF
DF
8/8
5/5
0/4** 8/8
Nd
Nd
Nd
Miklossy et al., 1995 [82] 24
10***
Brain DNA-DAPI 20/20
10/10***
0/4** Nd Nd
Miklossy et al., 1996, Miklossy, 1998 [83,84] 54 Brain IHC 32/32
12/12*
0/10** Nd
Nd
Nd
Nd
McLaughlin et al., 1999 [90] 7
28
Brain
Bl
DF, EM 0/7
1/22 0/6
Nd
Nd
Nd
Nd
Total: Various types of spirochetes detected using neutral techniques
Brain: AD N = 102, AD 64/71, CTRL 0/31”, P = 4.8 × 10
-18,O R ” = 274, 95% CI = 32-11345
Brain: AD, mild AD N = 114, AD 76/83, CTRL 0/31”,P=1×1 0
-19,O R ” = 325, 95% CI = 38-13440
Brain, Bl, CSF: AD, mild AD N = 147, AD 82/110, CTRL 0/37”, P = 1.1 × 10
-15,O R ” = 105, 95% CI = 13-4329
Periodontal pathogen spirochetes
Riviere et al, 2002 [96] 34 Brain, PCR, IHC 15/16 6/18 Nd Nd
Total: Periodontal pathogen spirochetes detected in the brain
Brain: AD, N = 34, AD 15/16, CTRL 6/18, P = 3.6 × 10
-4, OR = 30, 95%CI = 2.8-1364
Borrelia burgdorferi
MacDonald & Miranda1987 [98] 2 Brain IHC 1/1 0/1 + Nd
MacDonald, 1988 [99] 1 Brain DF, IHC 1/1 + Nd
Pappolla et al., 1989 [103] 10 Brain EM, IHC, Wbl 0/6 0/4 - Nd
Miklossy, 1993 and Miklossy et al., 2004 [70,85] 27*** Brain Bl, CSF Cult, IHC, EM, ISH, 16SrRNA 3/14*** 0/13*** 3/14 2/14
Miklossy, 1993 [70] 1 Brain IHC 1/1 Nd 1/1
Gutacker et al., 1998 [104] 10 Brain PCR 0/10 - Nd
Marques et al., 2000 [105] 30 Brain PCR 0/15 0/15 Nd Nd
Riviere et al., 2002 [96] 34*** Brain PCR, seq 5/16*** 1/18*** Nd Nd
Meer-Scherrer et al., 2006 [100] 1 Brain PCR 1/1 Nd 1/1
MacDonald, 2006 [101,102] 11 Brain PCR, IHC 7/10 0/1 Nd 1/1
Total: All studies detecting Borrelia burgdorferi
Brain: AD N = 127, AD 19/75, CTRL 1/52, P = 2.9 × 10
-4, OR = 17, 95%CI = 2-732
Total: All studies detecting spirochetes
Brain: AD N = 202, AD 90/131, CTRL 6/71, P = 1.7 × 10
-17, OR = 23, 95%CI = 9-71
Brain: AD, mild AD N = 214, AD 102/143, CTRL 6/71, P = 1.5 × 10
-19, OR = 26, 95% CI = 10-80
Brain, Bl, CSF: AD, mild AD N = 247, AD 108/170, CTRL 6/77, P = 1.5 × 10
-17, OR = 20, 95% CI = 8-60
Data reviewed in the literature with respect to the detection of all types of spirochetes using neutral techniques and the specific detection of periodontal pathogen
Treponemas and Borrelia burgdorferi. Results of the statistical analysis are given for each group and for all studies together. N = total number of cases investigated, AD =
Alzheimer disease, CTRL = control, Mat = material, Meth = methods, Cult = culture, Serol = serology, AD = Number of AD cases positive for spirochetes/number of AD
cases analyzed, CTRL = Number of control cases positive for spirochetes/number of control cases analyzed, Bl = blood, CSF = cerebrospinal fluid, EM = electron
microscopy, AFM = atomic force microscopy, DF = dark field microscopy, HC = histochemistry (Warthin and Starry, Bosma-Steiner silver stain for spirochetes), IHC =
immunohistochemistry, ISH = in situ hybridization, PCR = polymerase chain reaction, Bb = Borrelia burgdorferi, Wbl = Western blot, P = exact value of the significance
calculated by the Fischer test, OR = Odds Ratio, CI = 95% confidence interval, + = positive, - = negative, Nd = not done, seq = sequence analysis, * = cases with mild or
moderate AD-type cortical changes, ** = controls without any AD-type changes, *** = cases from previous studies, which were subtracted when the total number of
cases of studies were considered, “ = the number of 0 positive control was changed to 1 in order to calculate the exact OR and CI values.
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are identical to those of B. burgdorferi [85,86]. Electron
microscopic analysis demonstrated that they possess 10-15
endoflagella representative of B. burgdorferi species. 16S
rRNA gene sequence analysis definitely identified the cul-
tivated spirochetes as Borrelia species sensu stricto (s. s.)
[85]. In two of these AD cases post mortem serological
analyses of blood and cerebrospinal fluid (CSF) have
revealed a positive serology for B. burgdorferi fulfilling the
diagnostic criteria of the Center for Disease Control
(CDC). B. burgdorferi specific antigens and genes were
detected in the brains of these three AD patients where
B. burgdorferi was cultivated. Neurofibrillary tangles were
also immunoreactive with specific anti-B. burgdorferi anti-
bodies and Borrelia antigens were co-localized with Ab.
Using in situ hybridization (ISH) B. burgdorferi specific
OspA and flagellin genes were detected in senile plaques
and in a number of neurofibrillary tangles [85]. Impor-
tantly, the cortical distribution of spirochete masses or
colonies was identical to that of senile plaques. The patho-
logical changes observed in the brain were similar to those
occurring in the atrophic form of general paresis and in
AD.
B. burgdorferi specific antigens were observed in the
brain in an additional AD patient with concurrent
Lyme neuroborreliosis [70]. Using species-specific
PCR, B. burgdorferi DNA was detected in the brains in
5o f1 6A Dp a t i e n t sa n di no n eo f1 8c o n t r o l s[ 9 6 ] .I n
these 6 positive cases (5 AD and 1 control) B. burgdor-
feri co-infected with oral Treponema spirochetes. B.
burgdorferi specific DNA was detected by PCR in the
brain of an additional patient with concurrent AD and
Lyme neuroborreliosis [100] and in the hippocampus
in 7 of 10 pathologically confirmed definite AD cases
using PCR or ISH [101,102] (Table 1).
Pappolla et al., [103] who failed to detect B. burgdorferi
in the brains of 6 AD cases and 4 controls concluded that
the possibility of a different spirochete in AD not detect-
able by their methods could not be excluded, considering
the possibility that several types of spirochetes may be
involved in AD. Indeed, the goal of initial studies was not
to show the involvement of B. burgdorferi alone in AD
b u tt h a to ft h ei n v o l v e m e n to fv a r i o u st y p e so fs p i r o -
chetes of the order Spirochaetales, including B. burgdor-
feri, oral, intestinal and other, yet uncharacterized
spirochetes [70,80-84,86]. The title of the initial report,
“Alzheimer’s disease - A spirochetosis?”, clearly indicates
this goal [70].
In the two other studies where B burgdorferi was not
detected in the brain, evidence is lacking whether the
analyzed AD patients suffered from Lyme neuroborre-
lisosis [104,105] (Table 2). We cannot expect to detect
B. burgdorferi in the brains of AD patients who have
no Lyme neuroborreliosis. An example is the analysis
of the involvement of T. pallidum in syphilitic demen-
tia. If we would like to demonstrate the involvement of
T. pallidum in dementia in a population without
syphilis, we cannot succeed, despite the established
fact that this spirochete can cause dementia. In order
to study the involvement of B. burgdorferi in AD, the
analysis of AD patients suffering from Lyme disease is
necessary.
Similarly, due to the low incidence of Lyme dementia
compared to AD, the analysis of the seroprevalence of
B. burgdorferi alone may be disappointing [104,106]
(Table 2). In such studies it is difficult to prove the
Table 2 Serological analysis of Borrelia burgdorferi in Alzheimer disease
Authors N Mat Meth AD CTRL Cult
Pappolla et al., 1989 [103] 47 CSF ELISA 2/16 2/31 Nd
Gutacker et al., 1998 [104] 27 Bl, ELISA, Wbl 1/27 Nd
Miklossy, 1993 and Miklossy et al., 2004 [70,85] 7 Bl, CSF ELISA, IFAT, Wbl 2/4 0/3 +
Miklossy, 1993 [70] 1 Bl ELISA 1/1 Nd
Meer-Scherrer et al., 2006[100] 1 Bl ELISA, Wbl 1/1 Nd
MacDonald, 2006 [101,102] 1 Bl ELISA, Wbl 1/1 Nd
Galbussera et al., 2008 [106] 98 Bl ELFA 1(+/-)/50 0/48 Nd
Total: Borrelia burgdorferi serology
Blood:N = 135, AD: 7/84 (8.3%), CTRL: 0/51, (0%) “P = 0.2581, OR = 4.5, CI = 0.5-208
Blood & CSFN = 182, AD: 9/100 (9%), CTRL: 2/82 (2.43%), P = 0.1147, OR = 3.95, CI = 0.78-38
Data reviewed in the literature on the serological detection of B. burgdorferi specific antibodies in Alzheimer’s disease. There is no statistically significant
difference between AD and controls. The frequency of positive B. burgdorferi serology is more than eight times higher in the blood (7/84 versus 0/51) and almost
four times higher when taken together blood and CSF (4.3% versus 2.5%) in AD compared to controls. The Odds ratio values (4.5 and 3.95) indicate that positive
B. burgdorferi serology represents a risk for AD. N = total number of cases investigated, AD = Alzheimer disease, CTRL = control, Mat = material, Meth = methods,
Cult = culture, AD = Number of AD cases with positive serology to B. burgdorferi /number of AD cases analyzed, CTRL = Number of AD cases with positive
serology to B. burgdorferi /number of control cases analyzed, Bl = blood, CSF = cerebrospinal fluid, Wbl = Western blot, IFAT = Indirect Immunofluorescent
Antibody Test, ELISA = Enzyme-Linked Immunoabsorbent Assay, ELFA = Enzyme-Linked Fluorescence Assay, P = exact value of the significance calculated by the
Fischer test, OR = Odds Ratio, CI = 95% confidence interval, + = positive, Nd = not done, “ = the number of 0 positive control was changed to 1 in order to
calculate the exact OR and CI values.
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exclude the involvement of other spirochetes. As one
may expect, there is no statistically significant difference
between the positive blood and/or CSF serology between
such AD and control populations (P = 0.1147). However,
it is noteworthy, that the frequency of positive blood ser-
ology for B. burgdorferi is about 8 times higher in AD
and considering both blood and CSF serology about 4
times higher (9%) compared to controls (2.43%). The
high OR values (4.5 and 3.95, respectively) are also indi-
cative of a higher risk of positive B. burgdorferi serology
in AD. This is in harmony with the findings that in a sta-
tistically significant proportion of the AD population ana-
lyzed (25.3%) B. burgdorferi was detected in the brain. It
is also noticeable that in all those studies, which show
the involvement of B. burgdorferi in AD, the patients had
ap o s i t i v es e r o l o g yf o rB. burgdorferi and/or this spiro-
chete was cultivated from the brain in BSK medium
[70,85,98,99] or species-specific DNA was detected in the
brain [96] indicating that these AD patients suffered
from Lyme neuroborreliosis. Importantly, the majority of
AD patients analyzed in these studies came from ende-
mic areas of Lyme disease [70,85,98,99,101,102]. To con-
sider, that the results may also vary depending whether
the patients analyzed were living in endemic areas of
Lyme disease is also important, when analyzing
B. burgdorferi.
In future studies, to consider that several types of spiro-
chetes can co-infect in AD [96] and that spirochetes fre-
quently exhibit pleomorphism in host tissues [89] is also
essential. In view of an infectious origin of AD the use of
appropriate healthy control population without AD-type
cortical changes and without other neuro-psychiatric dis-
orders is also essential.
Taken together, these observations derived from var-
ious laboratories show that several types of spirochetes
can infect the brain in AD and co-infection with several
types of spirochetes occurs. As expected, the frequency
of periodontal pathogen spirochetes is higher compared
to that of B. burgdorferi, which is present in less then one
third of the AD cases analyzed. The significantly higher
frequency of B. burgdorferi in the brain of AD patients,
the high risk factor and the results of the multifaceted
analysis in three AD patients with concurrent Lyme neu-
roborreliosis, where B. burgdorferi was cultivated from
the brain and species specific antigens and DNA were
present in the cerebral cortex show that B. burgdorferi is
involved in the pathogenesis of a subset of AD cases [85].
Analysis of the association of spirochetes and AD
Based on the substantial data available in the literature,
contingency tables were used to analyze the strength of
the association between spirochetes and AD. Fisher test
was used to assess whether thed i f f e r e n c eb e t w e e nt h e
occurrence of spirochetes in AD and controls is statisti-
cally significant. Odds ratio (OR) and 95% confidence
interval (CI) values were also computed. If in the con-
trol group the number of positive cases was 0 in order
to calculate OR and 95% CI 1 positive control case was
added (Table 1).
In those studies where all types of spirochetes were
detected employing neutral techniques (Table 1, Figure 1),
spirochetes were observed in the brain in 90.1% (64/71) of
AD cases and were absent in controls without any AD-
type changes (Table 1). The difference was significant (P =
4.8. × 10
-18; OR = 274, 95% CI = 32-11345, N = 102).
When cases with mild or moderate AD-type changes were
also included as preclinical stages of AD, 91.5% of the
cases (76/83) were positive (P = 1 × 10
-19; OR = 325, 95%
CI = 38-13440, N = 114). The difference remains signifi-
cant when those cases were also included where spiro-
chetes were analyzed in the blood (P = 1.1 × 10
-15,O R=
105, 95% CI = 13-4329).
The association between periodontal pathogen spiro-
chetes and AD was statistically significant as well (Table 1,
Figure 2). They were detected in the brain in 93.7% of AD
Figure 1 Association of spirochetes with Alzheimer’sd i s e a s e .
The frequency of spirochetes is significantly higher in the brains of
Alzheimer patients compared to controls. The statistical analysis is
based on the cumulative data of the literature entered in Table 1.
The association is statistically significant in the four groups analyzed:
in the group where all types of spirochetes were detected using
neutral techniques (All spirochetes), in the group of oral periodontal
pathogen spirochetes (Oral spirochetes), in the group where Borrelia
burgdorferi was detected alone (B. burgdorferi) and in the group
where all studies were considered (All studies).
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-4;O R=3 0 ;
95% CI = 2.8-1364; N = 34).
B. burgdorferi (Table 1, Figure 1) was observed 13
times more frequently in the brain in AD (19/75, 25.3%)
compared to controls (1/52, 1.9%) (P = 2.9 × 10
-4,O R=
17; 95% CI: 2 - 732; N = 127). The low prevalence of
Lyme disease compared to AD is well reflected by the
lower frequency (25.3%) of B. burgdorferi compared to
the higher, more than 90% frequency of all types of spir-
ochetes detected with neutral techniques or the highly
prevalent periodontal pathogen spirochetes.
When considering all studies (Table 1, Figure 1) detect-
ing all types of spirochetes and their specific species, their
frequency was 8 times higher in the brain in AD (90/
131 = 68.7%) compared to controls (6/71 = 8.45%). The
difference is statistically significant (P = 1.7 × 10
-17;O R=
23; 95% CI = 9-71, N = 202). The association remains
strongly significant when the 12 cases with mild AD-type
changes (P = 1.5 × 10
-19, OR = 26, 95% CI = 10-80, N =
214) or those cases where spirochetes were analyzed in
the blood were also included (P = 1.5 × 10
-17,O R=2 0 ,
95% CI = 8-60, N = 247). If considering errors, which
may arise from those studies where the detection of spir-
ochetes was restricted to B. burgdorferi alone, without
considering other spirochetes ,t h ep e r c e n t a g eo fs p i r o -
chetes in AD would be even higher than 68.7%. This is
supported by the high percentage of spirochetes in stu-
dies where all types of spirochetes were detected using
neutral techniques (90.1%) or where the highly prevalent
periodontal pathogen spirochetes were analyzed (93.7%).
Taken together, these results show a strong, statisti-
cally significant association between spirochetes and AD
and show that these microorganisms represent a strong
risk for AD.
Further experimental evidence for a causal
relationship between spirochetes and AD
Additional studies have brought further evidence in sup-
port of a probable causal relationship between spirochetes
and AD. For these experimental studies B. burgdorferi was
employed, as this spirochete can be cultivated in synthetic
medium and maintained in pure culture.
When primary neuronal and glial cells and brain cell
aggregates were exposed to B. burgdorferi sensu stricto
spirochetes (B. burgdorferi strain B31 and strains ADB1
and ADB2 cultivated from the brains of AD patients),
Thioflavin S positive and Ab-immunoreactive “plaques” as
well as tangle- and granular lesions similar to granulova-
cuolar degeneration were induced [107]. Spirochete
induced Ab accumulation was identified by Western blot
and the b-pleated sheet conformation of the amyloid in
spirochete-induced plaques was detected in situ using Syn-
chrotron InfraRed MicroSpectroscopy (SIRMS). Borrelia
induced tau phosphorylation and increased AbPP levels
represented additional experimental evidences that spiro-
chetes are able to induce an AD-type host reaction [107].
Both, reference Borrelia spirochetes (B31) and those cul-
tivated from the brains of AD patients (ADB1 and ADB2
strains) invaded neurons and glial cells and induced
nuclear fragmentation, indicating that these spirochetes
are invasive [89,107]. They were located extra- and intra-
cellularly. Their intracellular location indicates that they
can be protected from destruction by the host immune
reactions [70,89,107]. These results show that in an analo-
gous way to T. pallidum they can persist in the brain and
cause dementia, cortical atrophy and the pathological hall-
marks of AD.
It is noteworthy that spirochetes frequently co-infect
with other bacteria and viruses. Co-infection of T. palli-
dum with other bacteria, various Herpes viruses and
Candida albicans was frequently observed in syphilis
[91]. In Lyme disease, in addition to various co-infections
transmitted by tick-bite (e.g. bartonellosis, ricketttsiosis,
babesiosis etc.) B. burgdorferi frequently co-infects with
other pathogens, which are independent of the tick-bite,
e.g. Clamydophyla pneumoniae (C. pneumonia) [108] and
Herpes viruses [108-111]. Co-infection of spirochetes
with C. pneumonia also occurs in a Lyme-like tick-borne
disease in Brazil [112]. Intriguingly, C. pneumoniae
[113,114] and Herpes simplex type 1 (HSV-1) [115,116]
were also detected in the brain in AD, suggesting that
similarly to Lyme disease and syphilis, concurrent infec-
tion with several pathogens may frequently occur in AD
as well.
Figure 2 Association of oral invasive periodontal Treponema
(T.) spirochetes with Alzheimer’s disease. Using species specific
PCR and antibodies six of seven periodontal pathogen spirochetes
analyzed were detected in the brains of AD patients [96], (Table 1).
The association of oral Treponemas with Alzheimer’s disease is
statistically significant [96], (Table 1).
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including T. denticola and Herpes viruses are also linked
to atherosclerosis [2,3,7], cardiovascular disorders
[4,6,117] and diabetes mellitus [16,118,119], which indi-
cate that these infectious agents, via hematogenous disse-
mination, may reach and infect various organs distant
from the site of the primary infection. In agreement with
this view, epidemiological studies revealed a close asso-
ciation between periodontal diseases and these chronic
disorders [120]. It is noteworthy that AD is not only asso-
ciated with these chronic inflammatory disorders but
with chronic periodontal disorders as well [121].
Mechanisms involved in spirochete-host
interaction and their similarities to AD
The strong neurotropism of spirochetes is well known.
Spirochetes can invade the brain and generate latent, per-
sistent infection [29,63,65]. In addition to hematogenous
dissemination, they can spread via the lymphatics and
along nerve fiber tracts [63,91]. Accordingly, periodontal
invasive spirochetes were detected along the trigeminal
nerve and in trigeminal ganglia [96]. They might also pro-
pagate along the fila olfactoria and tractus olfactorius,
which would be in harmony with the olfactory hypothesis
[122-124] and with previous observations showing that the
olfactory tract and bulb are affected in the earliest stages
of the degenerative process in AD [125].
Spirochetes attach to host cells through their surface
components, including collagen-binding proteins, bacterial
amyloids and pore forming proteins [126-131]. Through
activation of plasminogen and factor XII, bacterial amy-
loids contribute to inflammation and modulate blood coa-
gulation [132].
The innate immune system enables host cells to
recognize spirochetes, execute proinflammatory
defenses, and start adaptive immune responses.
Pattern recognition receptors, located on the cell mem-
brane of various cells, particularly on phagocytes and
microglia recognize unique structures of spirochetes. The
largest family of pattern recognition receptors is that of
Toll-like receptors (TLRs). TLRs are also present in the
brain [133]. Macrophages and microglia activated
through TLR signaling secrete chemokines and cytokines
and express various proinflammatory molecules for the
removal of pathogens and affected cells. Spirochetes and
their surface lipoproteins activate TLR signaling through
CD14 [134,135]. As an example, tri- or di-acylated lipo-
proteins of B. burgdorferi bind to lipopolysaccharide
binding protein (LBP), which activates TLR signaling
through CD14 [136].
It is noteworthy, that in addition to spirochetal antigens
and DNA, D-amino acids and bacterial peptidoglycan,
two natural constituents of Prokaryotic cell wall unique
to bacteria, were also detected in the brain in AD
[83,84,137,138]. Pattern recognition receptors are upre-
g u l a t e di nt h eb r a i ni nA D ,a n dT L R 2a n dT L R 4g e n e
polymorphisms influence the pathology of AD [139,140].
Activation of microglia with TLRs 2, 4 and 9 ligands
markedly increases Ab ingestion in vitro [141]. Finally,
stimulation of the immune system through TLR9 in
AbPP (Tg2576) transgenic mice results in reduction of
Ab deposits [142].
Once microorganisms are recognized, the activation of
the innate immune system induces phagocytosis and bac-
teriolysis through the formation of the membrane attack
complex (MAC, C5b9) [143-145] and promotes inflamma-
tory responses. Activation of the clotting cascade generates
bradykinin, which increases vascular permeability. Spiro-
chetes activate both the classic and alternative pathways
and induce acute phase proteins. Serum amyloid A (SAA)
and C Reactive Protein (CRP) levels are elevated in T. pal-
lidum and B. burgdorferi infections [146,147]. Through
their ability to induce the production of tumor necrosis
factor (TNF) by macrophages, spirochete lipoproteins play
an important role in systemic and local inflammatory
changes that characterize spirochetal infections [148].
In Alzheimer’s disease, activated microglia that are
designed to clean up bacteria and cellular debris surround
senile plaques and extracellular neurofibrillary tangles
[53]. Both the cellular and humoral components of the
immune system reactions [48-53] and critical constituents
of the classical and alternative complement pathways are
associated with AD lesions [51,52,149].
Spirochetes are able to evade host defense mechanisms
and establish latent and slowly progressive chronic infec-
tion. They employ a broad range of strategies to overcome
antigenic recognition, phagocytosis and complement lysis.
Blockade of the complement cascade allows their survival
and proliferation even in immune competent hosts. Com-
plement resistant strains of B. burgdorferi possess five
Complement Regulatory Acquiring Surface Proteins
(CRASPS), which bind to factor H (FH) and factor-H like
protein-1 (FHL-1) of the alternative pathway [145,150].
Binding to the surface of spirochetes host FH and FHL-1
promotes the formation of inactive iC3b from C3b pre-
venting MAC lysis. B. burgdorferi spirochetes possess a
CD59-like complement inhibitory molecule as well [151],
which by interacting with C8 and C9, inhibits binding of
the opsonizing components C4b and C3b to MAC and
consequently, prevents bacteriolysis [150]. Impaired com-
plement lysis was also observed in T. pallidum infection
[143].
B. burgdorferi protects itself from destruction by the
host adaptive immune system as well. It induces interleu-
kin-12 (IL-12), a cytokine critical for driving cellular
responses toward Th1 subset [152-154]. This shift retards
antibody production by Th2 cells against the spirochete.
Intracellular survival of spirochetes also confers protection
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of spirochetes will result in their survival and proliferation
in the brain. Their accumulation in the cerebral cortex
will lead to the formation of senile plaques, tangles and
granulovacuolar-like degeneration as shown by historic
observations in syphilis [61,62] and by current observa-
tions and in vitro experiments reviewed here (Fig. 7).
Accumulation in the brain of “paralytic iron” is char-
acteristic in general paresis [59]. Free iron abolishes the
bactericidal effects of serum and strongly enhances bac-
terial virulence [155-157]. It is necessary for bacterial
growth and plays a pivotal role in infection and inflam-
mation [155-157]. Iron increases the formation of reac-
tive oxygen intermediates causing lipid peroxidation and
subsequent oxidative damage of proteins and nucleic
acids [155-157]. Iron, also accumulates in the brain in
AD [155,158-160].
The production of reactive oxygen and nitrogen inter-
mediates by innate immune cells is an effective host-
defense mechanism against microbial pathogens. Activation
of macrophages and other host cells by bacteria or LPS,
including spirochetes and their lipoproteins generates sub-
stantial amount of nitric oxide (NO) [157], which is critical
in bacterial clearance [161]. Nitric oxide also plays a central
role in AD [162].
Chronic bacterial infections (e.g. rheumatoid arthritis,
leprosy, tuberculosis, syphilis, osteomyelitis) are fre-
quently associated with amyloid deposition. Based on
previous observations we have suggested that amyloido-
genic proteins might be an integral part of spirochetes
and could contribute to Ab deposition in AD [70].
Recent observations indeed showed that the BH (9-10)
peptide of a beta-hairpin segment of B. burgdorferi
outer surface protein A (OspA) forms amyloid fibrils in
vitro, similar to human amyloidosis [163,164]. Recent
observations also show that amyloid proteins constitute
a previously overlooked integral part of the cellular
envelope of many bacteria [163-168]. Bacterial amyloids
have important biological functions and contribute to
bacterial virulence and invasion of host cells [165,166].
Genetic mutations occurring in AD (AbPP, Presenilin 1
and 2) are related to the processing of AbPP and result in
increased production of Ab 1-42 and Ab 1-43 [169]. AbPP
revealed to be a proteoglycan core protein [170] and is
involved in the regulation of immune system responses
and in T cell differentiation [171-173]. Recent observations
showed that Ab is an innate immune molecule and
belongs to the family of antimicrobial peptides AMPs
[174], which are involved in innate immune responses.
Consequently, genetic defects in AbPP, PS-I and PS-II
should be associated with an increased susceptibility to
infection. ApoE4, an important risk factor for AD, is also
risk factor for infection and enhances increased expression
of inflammatory mediators [175,176].
Promoter polymorphisms in pro-inflammatory cytokine
genes facilitate infections [177]. TNF-a plays a critical role
in host defenses against infection [178,179]. The influence
of TNF-a on T. pallidum and B. burgdorferi infections has
been repeatedly reported [153,180]. Human Leukocyte
Antigen (HLA) gene polymorphism is a dominant marker
of susceptibility to infection, including B. burgdorferi infec-
tion [181]. TNF-a and HLA polymorphisms, which are
risk factors for infection, substantially influence the risk of
AD as well [182-184].
Analysis of causal relationship between
spirochetes and AD following Koch’s and Hill’s
postulates
Koch’s postulates
Koch’s postulates were proposed to establish causal rela-
tionship between pathogens and specific diseases [34].
Following Koch’s postulates I and II, the microorganism
should be isolated from the affected tissue and grown in
pure culture. Regarding Koch’s postulates III and IV, the
cultured microorganism should cause disease when intro-
duced into a healthy host and must be re-isolated and
identified as being identical to the original causative agent.
Spirochetes were cultivated from the brains of AD
patients in a modified Noguchi medium and maintained
in culture for about 1 month [70]. B. burgdorferi was culti-
vated from the brains of 5 out of 8 AD patients who suf-
fered from Lyme neuroborreliosis and was maintained and
propagated in pure culture [70,85,89], which fulfills Koch’s
postulates I and II. With respect to Koch’s postulates III
and IV the defining pathological and biological hallmarks
of AD were reproduced in vitro not only in primary mam-
malian neuronal and glial cell cultures but in CNS organo-
typic cultures as well, which aim to replace in vivo studies
[107]. B. burgdorferi (strains B31, ADB1, ADB2) was also
recovered in pure culture from infected cell cultures [89].
In vivo studies might bring further evidence with respect
to Koch’s postulates III and IV. Following Koch’sp o s t u -
lates the causal relationship between B. burgdorferi and
dementia is much stronger, than in the case of T. palli-
dum, which is known to cause dementia, but cannot be
cultivated in pure culture.
Koch himself acknowledged that the application of his
postulates to establish causality is sometimes difficult and
suggested that his criteria should be used as guidelines
[35]. Indeed, like T. pallidum, several other bacteria and
viruses cannot be grown in pure culture and based on his
criteria to establish causality in chronic disorders is lim-
ited. In order to address this question, new criteria were
proposed by Hill [36].
A previous review [185], on the analysis of association of
infectious agent with AD following Hill’s criteria con-
cluded that the “treatment of chronic infection may
become an important part of AD prevention and therapy”.
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new data were included in this study.
Therefore, based on the substantial data available on
the detection of spirochetes in AD, we analyzed the
probability of a causal relationship following Hill’sn i n e
criteria [36].
Hill’s postulates
1. Strength of the association
In agreement with Honjo et al. [185], the statistical ana-
lysis shows a significant association between spirochetes
and AD (Table 1).
2. Consistency of the association
Following Hill, the consistency of the association
demands whether the results were “repeatedly observed
by different persons, in different places, circumstances
and times?”. In 14 studies [70,80-85,90,96,98-102] spiro-
chetes were detected in AD. Various authors in diverse
laboratories, in different countries, using different tech-
niques have detected spirochetes in AD, fulfilling Hill’s
claim for the consistency of association. In three studies
[103-105], which failed to show the involvement of
B. burgdorferi in AD, evidence is lacking whether the
AD patients had a positive serology for B. burgdorferi,a s
for this goal, the analysis of AD populations suffering
from Lyme neuroborreliosis would be essential. As men-
tioned by Pappolla et al. [103], the possibility of the
involvement of other spirochetes in AD cannot be
excluded. In another study on the analysis of sero-preva-
lence of B. burgdorferi in AD, due to the low incidence
of Lyme dementia compared to AD can explain the
negative result [106].
3. Specificity of the association
Spirochetes and spirochete specific antigens and DNA
associated with lesions defining AD indicate the specifi-
city of the association.
4. Temporality of the association
The temporal relationship of the association, is “... a
question which might be particularly relevant with dis-
eases of slow development... Have they already con-
tracted it before?” T. pallidum infection in the atrophic
form of general paresis is a historical example of tem-
poral relationship between spirochetal infection and
slowly progressive dementia [29,63,65]. Spirochetes were
detected in AD patients with early stages of plaque-,
tangle- and curly fiber-formation [83,84] indicating that
infection takes place long before the diagnosis of
dementia is made [70].
5. Biological gradient of the association
That spirochetes are able to form plaque-, tangle- and
curly fiber-like lesions [70,85,107] and their number
progressively increases in the brains of patients with
mild, moderate [83,84], and severe AD-type changes
[70,80-87] fulfill this condition.
6. Plausibility of the association
T. pallidum in the atrophic form of general paresis
causes dementia, brain atrophy and Ab deposition similar
to the pathological and biological hallmarks of AD
[61,62,67,85]. That AD-type pathological changes were
also induced in vitro by B. burgdorferi and were observed
in the brains of patients with concurrent AD and Lyme
neuroborreliosis indicate that chronic spirochetal infec-
tion can cause dementia.
7. Coherence of the association
As proposed by Hill, the cause-and-effect interpretation of
t h ed a t as h o u l dn o ts e r i o u s l yc onflict with the generally
known facts of the natural history and biology of the dis-
ease [36]. That a slow acting unconventional infectious
agent acquired at an early age and requiring decades to
become active may be involved in AD was never discarded
[186,187]. Fischer, Alzheimera n dt h e i rc o l l e a g u e sd i s -
cussed the possibility that microorganisms may play a role
in the formation of senile plaques and described similari-
ties in the clinical and/or pathological manifestations of
Alzheimer disease and general paresis [32,33,58,59,67,86].
Chronic spirochetal infection can cause slowly progressive
dementia, cortical atrophy, chronic inflammation and Ab
deposition, which are indistinguishable from those occur-
ring in AD [29,61,62,67,85,86]. Spirochete-host interac-
tions result in various immune responses, free radicals,
apoptosis and amyloid deposition, which are typical of AD
[86]. The genetic defects occurring in AD can facilitate
infection as well [for a review see 86]. Spirochetal infec-
tions cause cerebral hypoperfusion [188-190], cerebrovas-
cular lesions and severely disturbed cortical capillary
network [29,191,192], which are also important factors in
the pathogenesis of AD [193-199]. As in AD, mixed forms
of dementia due to cortical atrophy and vascular lesions
frequently occur in neurospirochetoses [29,63], further
strengthening the coherence of the association. All these
observations indicate that, the association is in harmony
with the natural history and biology of AD.
8. Experimental evidences
Following exposure of primary mammalian neuronal and
glial cells and brain organotypic cultures to spirochetes,
lesions similar to the defining pathological and biological
hallmarks of AD were produced [107] representing
experimental evidence in favor of a causal relationship
between AD and spirochetes. These experimental data
[107,89] indicate that as observed in syphilis [29,61,62]
and Lyme neuroborreliosis [85,89], the evasion of spiro-
chetes can result in their survival and proliferation and
the production of lesions similar to senile plaques, tan-
gles and granulovacuolar-degenerations (Figure 3). Addi-
tional experimental data include transmission of Ab
amyloidosis to experimental animals [200-203], the
observations showing the immune regulatory function of
APP [171-173], the antimicrobial properties of Ab [174]
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lowing antibiotic treatment [204-208]. Further research
and clinical trials would be primordial.
9. Analogy of the association
The analogy of clinical and pathological hallmarks of
AD to those of the atrophic form of general paresis and
Lyme neuroborreliosis as revealed by historic observa-
tions and based on retrospective studies meets this con-
dition [29,33,61,62,67,85,86].
Taken together, the analysis of historic and recent
data available in the literature following Koch’sa n d
Hill’s criteria is in favor of a causal relationship between
neurospirochetosis and AD.
Conclusions
Various types of spirochetes, including B. burgdorferi,
and six periodontal pathogen spirochetes (T. socranskii,
T. pectinovorum, T. denticola, T. medium, T. amylo-
vorum and T. maltophilum) were detected in the brains
of AD patients. The pathological and biological hallmarks
of AD, including increased AbPP level, Ab deposition
and tau phosphorylation were induced by spirochetes in
vitro. The statistical analysis showed a significant associa-
tion between spirochetes and AD. The strongly signifi-
cant association, the high risk factor and the analysis of
data following Koch’s and Hill’s criteria, are indicative of
a causal relationship between neurospirochetoses and
AD.
Spirochetes are able to escape destruction by the host
immune reactions and establish chronic infection and sus-
tained inflammation. Inv i v ostudies with long exposure
times will be necessary to efficiently study the sequence of
events and the cellular mechanisms involved in spirochete
induced AD-type host reactions and Ab-plaque, “tangle”
and “granulovacuolar” formation. The characterization of
all types of spirochetes and co-infecting bacteria and
viruses is needed, in order to develop serological tests for
Figure 3 Schematic representation of spirochetal invasion of the cerebral cortex reproducing the pathological hallmarks of
Alzheimer’s disease. Spirochetes, in an analogous way to Treponema pallidum, form argyrophilic “plaques”, colonies or masses along the
cerebral cortex. Accumulation of spirochetes in masses reproduces the morphology of amorphous, immature and mature plaques. Agglutination
of spirochetes in the center results in a homogeneous central core, which attract microglia. Spirochetes invading neurons lead to the formation
of neurofibrillary tangles, and their pleomorphic granular form to granulovacuolar degeneration. Individual spirochetes disseminate along the
cerebral cortex forming neuropil threads or curly fibers. Invasion of astrocytes by spirochetes can results in a similar granular pathology as in
neurons. Spirochetes can also invade microglia, which may lead to their dysfunction and diminish their capacity to fight infection. Lesions similar
to plaques, tangles and granulovacuolar degeneration were all reproduced by exposure of mammalian CNS cells and organotypic cultures to
spirochetes [107].
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thought to begin long before the diagnosis of dementia is
made therefore, an appropriate targeted treatment should
start early in order to prevent dementia.
Persisting spirochetal infection and their persisting
toxic components can initiate and sustain chronic
inflammatory processes through the activation of the
innate and adaptive immune system involving various
signaling pathways. In the affected brain the pathogens
and their toxic components can be observed, along with
host immunological responses. The response itself is
characteristic of chronic inflammatory processes asso-
ciated with the site of tissue damage. The outcome of
infection is determined by the genetic predisposition of
the patient, by the virulence and biology of the infecting
agent and by various environmental factors, such as
exercise, stress and nutrition.
The accumulated knowledge, the various views, and
hypotheses proposed to explain the pathogenesis of AD
form together a comprehensive entity when observed in
the light of a persisting chronic inflammation and amyloid
deposition initiated and sustained by chronic spirochetal
infection. As suggested by Hill, once the probability of a
causal relationship is established prompt action is needed.
Similarly to syphilis, one may prevent and eradicate
dementia in AD. The impact on healthcare costs and on
the suffering of the patients would be substantial.
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